ghk cu peotide GHK-CU – Research Peptide GHK-Cu Peptide Therapy: Anti-Aging &

We clean the area with an alcohol swab and let it dry

Benefits (Research Focus) Combined pathway research studied for paired investigation of pentadecapeptide (BPC-157) and -thymosin (TB-500) signaling Angiogenesis & vascularization investigated for combined effects on new blood vessel formation and endothelial pathway endpoints Connective tissue research explored for tendon and ligament repair endpoints in preclinical recovery models Cell migration & cytoskeletal dynamics examined for combined fibroblast migration and actin sequestration activity Comparative pharmacology researched for paired-compound vs single-compound endpoint differences in tissue repair models What Researchers Look At Comparative angiogenesis markers (VEGF, integrins) versus single-compound BPC-157 or TB-500 administration Fibroblast migration, collagen synthesis, and wound closure rates in combined-treatment protocols G-actin / F-actin dynamics and cytoskeletal reorganization in cell migration assays Tendon-to-bone healing endpoints in surgical research models Nitric oxide pathway modulation and anti-inflammatory signaling profiles Quick Specs Form: Lyophilized white powder (dual-component blend) BPC-157: 5 mg per vial TB-500: 5 mg per vial Total Peptide Content: 10 mg per vial Quantity: 1 vial Appearance: White to off-white lyophilizate Reconstitution: Bacteriostatic or sterile water (added by the end researcher) Purity: 99% by HPLC (per component) Identity: MS-verified (per COA) Storage: Protect from light Identity Basics Compound 1: BPC-157 (Body Protection Compound-157) Class: Synthetic pentadecapeptide

102-484, 4237(c), October 1992

A peer-reviewed study in the Journal of Pharmaceutical Sciences confirming that temperature and moisture are the primary drivers of lyophilized peptide degradation during storage provides the scientific basis for these refrigeration requirements

Reported examples included: Three hernia repairs: cleared to return to road cycling after 4 weeks instead of the expected 12 to 16 weeks

Ferumoxytol Injection is indicated for: Treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD), including those on dialysis and non-dialysis-dependent